We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Affimed (AFMD) Surges On Collaboration Contract With Roche
Read MoreHide Full Article
Shares of Affimed Inc. (AFMD - Free Report) were up a massive 246.8% post announcement of a cancer collaboration agreement with Roche Holding’s (RHHBY - Free Report) subsidiary, Genentech, on Monday Aug 27.
In fact, the stock has skyrocketed 327% year to date, comprehensively outperforming the industry’s increase of 2.4%.
Both companies have entered into a strategic collaboration deal to commercialize and develop a host of immunotherapeutic treatments for multiple cancers.
Financial Details of the Deal
Per the terms of the contract, Affimed will receive an upfront payment of $96 million with potential for an additional $5 billion in milestone payments and royalties on sale. The transaction is expected to close in the third quarter of 2019, subject customary closing conditions and a clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Other Details
Affimed will discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech, using its proprietary Redirected Optimized Cell Killing platform, which utilizes both NK cells (natural killer cells) and T-cells.
The agreement will include other pipeline candidates from Affimed’s ROCK platform, which are under evaluation for multiple solid and hematologic tumors. While Affimed and Genentech will carry out early-stage and late-stage research phases, Genentech will be solely responsible for clinical development and commercialization worldwide.
The transaction looks to be a strategic fit for Affimed as it will boost its cashflow to a great extent. The influx of $96 million will be a great drive for the company. Moreover, Affimed has potential back load of milestone payments worth $5 billion. Hence, the company will not need to raise cash.
Illumina’s earnings estimates have been raised 12.1% for 2018 and 10% for 2019 over the past 60 days. The stock has soared 57.8% so far this year.
Gilead Sciences’ earnings estimates have been moved 7.5% north for 2018 and 1.9% for 2019 over the past 60 days. The stock has gained 4.6% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Affimed (AFMD) Surges On Collaboration Contract With Roche
Shares of Affimed Inc. (AFMD - Free Report) were up a massive 246.8% post announcement of a cancer collaboration agreement with Roche Holding’s (RHHBY - Free Report) subsidiary, Genentech, on Monday Aug 27.
In fact, the stock has skyrocketed 327% year to date, comprehensively outperforming the industry’s increase of 2.4%.
Both companies have entered into a strategic collaboration deal to commercialize and develop a host of immunotherapeutic treatments for multiple cancers.
Financial Details of the Deal
Per the terms of the contract, Affimed will receive an upfront payment of $96 million with potential for an additional $5 billion in milestone payments and royalties on sale. The transaction is expected to close in the third quarter of 2019, subject customary closing conditions and a clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Other Details
Affimed will discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech, using its proprietary Redirected Optimized Cell Killing platform, which utilizes both NK cells (natural killer cells) and T-cells.
The agreement will include other pipeline candidates from Affimed’s ROCK platform, which are under evaluation for multiple solid and hematologic tumors. While Affimed and Genentech will carry out early-stage and late-stage research phases, Genentech will be solely responsible for clinical development and commercialization worldwide.
The transaction looks to be a strategic fit for Affimed as it will boost its cashflow to a great extent. The influx of $96 million will be a great drive for the company. Moreover, Affimed has potential back load of milestone payments worth $5 billion. Hence, the company will not need to raise cash.
Affimed N.V. Price and Consensus
Affimed N.V. Price and Consensus | Affimed N.V. Quote
Zacks Rank & Stocks to Consider
Affimed currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the pharma sector are Illumina, Inc. (ILMN - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Illumina’s earnings estimates have been raised 12.1% for 2018 and 10% for 2019 over the past 60 days. The stock has soared 57.8% so far this year.
Gilead Sciences’ earnings estimates have been moved 7.5% north for 2018 and 1.9% for 2019 over the past 60 days. The stock has gained 4.6% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>